Indefinite Delivery Contract 75D30124D18408
Award Date
1/2/24
Last Date to Order
2/28/25
Federal Agency
CDC Pittsburgh
Awardee
Astrazeneca Pharmaceuticals LP
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The IDC, valued at $24,672,000.00, is for the procurement of adult influenza vaccines for the 2020-2021 timeframe. As a multiple award IDC, this contract vehicle allows the CDC to issue task orders to AstraZeneca and other qualified vendors to fulfill adult influenza vaccine requirements....
This Indefinite Delivery Contract (IDC) is a multiple-award vehicle awarded by the Centers for Disease Control and Prevention (CDC), a civilian federal agency under the Department of Health and Human Services, to AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The contract has a ceiling value of $8,820,000.00 and a period of performance through February 28, 2025, for the procurement of adult influenza vaccines during the 2024-2025 flu season....
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), a civilian agency within the Department of Health and Human Services, to AstraZeneca Pharmaceuticals LP, a foreign-owned for-profit pharmaceutical manufacturer. The $131,584,000 contract is for the delivery of influenza vaccines for adult immunization programs under Section 317(j) of the Public Health Service Act. There was no set-aside used for this single-award IDC, which has a period...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to AstraZeneca Pharmaceuticals LP, a large foreign-owned pharmaceutical manufacturer, to provide adult influenza vaccines for the 2025-2026 season. The $9,050,000 multiple-award IDC has a period of performance through February 2026. As a large business, AstraZeneca did not receive a small business set-aside for this contract. AstraZeneca has a broad portfolio of federal contracts and...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) to AstraZeneca Pharmaceuticals LP, a foreign-owned pharmaceutical manufacturer, on December 31, 2024. The contract has a ceiling value of $51,900,000 and a period of performance through February 28, 2026. The primary purpose of this IDV is to procure pediatric influenza vaccines for the 2025-2026 season. AstraZeneca, as the prime contractor, will provide these vaccines to the CDC and potentially...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC), a civilian agency within the Department of Health and Human Services (HHS), to AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The contract, valued at $377,600,000.00, is for the procurement of influenza vaccines to support adult and pediatric immunization programs. AstraZeneca, a leading global biopharmaceutical company, has a history of providing...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) to Astrazeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The $47.2 million, multiple-award contract, with a period of performance through February 2021, is for the procurement of pediatric influenza vaccines. Astrazeneca is a leading global biopharmaceutical company that has supplied various pharmaceutical products, medical treatments, and medical...
This Indefinite Delivery Contract (IDC) was awarded by the Medical Supply Chain division of the Defense agency to AstraZeneca Pharmaceuticals LP, a large foreign-owned pharmaceutical manufacturer, with a ceiling value of $5,360,046.82 and a period of performance from November 16, 2016 to November 15, 2026. The contract is for the manufacture and distribution of various medical products, including influenza vaccines, COVID-19 treatments, monoclonal antibodies, and other pharmaceuticals. The...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to AstraZeneca Pharmaceuticals LP for the procurement of adult influenza vaccines for the 2022-2023 flu season. The contract has a ceiling value of $12,337,500.00 and a period of performance from the date of award on January 5, 2022 through February 28, 2023. The contract aims to procure a minimum of 100 doses and a maximum...
The Centers for Disease Control and Prevention (CDC) has awarded Astrazeneca Pharmaceuticals LP, a foreign-owned pharmaceutical manufacturer, an Indefinite Delivery Contract worth up to $75.52 million to provide pediatric influenza vaccines for the 2022-2023 season. The contract has a period of performance from January 5, 2022 through February 28, 2023. Under this contract, Astrazeneca will deliver between 100 doses to 50 million doses of influenza vaccine for children ages 0 through 18 to CDC...